Evaluation of ultrasonically nebulised solutions for provocation testing in patients with asthma

SANDRA D ANDERSON, ROBIN E SCHOEFFEL, M FINNEY

From the Department of Thoracic Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

ABSTRACT The airway response to the inhalation of ultrasonically nebulised distilled water was determined in 55 asthmatic patients and 16 normal subjects. We calculated the dose of water required to induce a 20% reduction (PD_{20}) in forced expiratory volume in one second (FEV_1) by measuring the output of the nebuliser and the volume ventilated by each subject. Forty-eight of the asthmatic patients had a PD_{20} of 9 ml or less but three patients required as much as 24 ml. A PD_{20} was not recorded in the normal subjects and the challenge was stopped after 33 ml. In 12 patients the challenge was repeated within six months and the airway response was shown to be reproducible at equivalent doses of water. In a separate group of 11 patients there was, however, a highly significant reduction in the percentage fall in FEV_1 when equivalent doses of water were given on two occasions 40 minutes apart. When the temperature of the inhaled water was increased from 22°C to 36°C eight of 10 patients had a similar change in FEV_1 with equivalent doses of water. The airways obstruction induced by the inhalation of water was readily reversed with salbutamol administered by aerosol. In some patients a challenge with water or 3.6% saline was repeated after pretreatment with sodium cromoglycate, atropine methonitrate, and verapamil hydrochloride, all given as aerosols. The airway response to the equivalent dose of water or saline was significantly reduced after treatment with sodium cromoglycate but not atropine or verapamil.

The measurement of the airway response to the inhalation of ultrasonically nebulised solutions of hypotonic and hypertonic solutions provides a new approach for the investigation of non-immunologically mediated bronchial reactivity.

We have previously measured airway reactivity to these solutions by determining the total volume of inhaled aerosol (that is, ventilation) required to reduce the forced expiratory volume in one second (FEV_1) by 20% of the pre-challenge value.¹ Other workers have measured changes in airway resistance after administering the inhaled solutions for a specified time, usually five minutes.² There are many different ultrasonic nebulisers in use and the output of aerosol is likely to vary between nebulisers. The measurement of the volume of inhaled aerosol or the time of aerosol delivery alone does not permit a comparison to be made between asthmatic patients

studied in different laboratories.

For this reason we have determined the delivered dose required to induce a 20% reduction in FEV_1 and compared the responses in FEV_1 to equivalent doses of water under different conditions. Furthermore, we have measured the proportion of a delivered dose which is retained by the patient. We have also studied the effects of sodium cromoglycate, atropine methonitrate, and verapamil hydrochloride on the airway response to the same dose of inhaled solution.

Methods

We studied 55 patients aged 11-56 years (mean $\pm$ SD 28.5 $\pm$ 10.8 years) with clinically recognised asthma who were taking beta-sympathomimetic aerosols regularly for control of their symptoms. All medications were withheld for at least four hours before any test. The protocol was approved by the ethics review committee and informed consent obtained. Sixteen non-asthmatic subjects volunteered as controls. The FEV_1 was measured (Minato, Autspirometer, Osaka, Japan, or Cavi-

Address for reprint requests: Department of Thoracic Medicine, Royal Prince Alfred Hospital, Missenden Road, Camperdown 2050, New South Wales, Australia.

tron Spirometer, California, USA) in each patient before and after the inhalation of ultrasonically nebulised distilled water and in some cases 3.6% saline.

The MistoO₂gen electronic nebuliser EN143A (California, USA) was used in all studies. This nebuliser delivers particles varying in size from 2 to 10 μm . The output of the nebuliser was measured by drawing known volumes of aerosol (range 10–110 l) through silica gel (2×500 g) at varying flow rates ($9\text{--}16\text{ l min}^{-1}$) with a motor blower pump (WE Collins, Massachusetts, USA). The aerosol was drawn intermittently (by turning two three-way taps) via hosing 67 cm or 149 cm long and 2.5 cm wide. Thus the rate and depth of normal human respiration could be simulated and the dose in millilitres delivered by the nebuliser recorded over a wide range of volumes. A regression equation was determined to relate the amount of water absorbed by the silica gel to the volume of aerosol which passed through the silica gel for each length of tubing.

For the inhalational challenge the patients breathed with a normal tidal volume (usually 500–1000 ml) through a two-way valve (Hans Rudolph, No 2700, Kansas, USA). Expired air passed through a canister containing 500 g silica gel and then a Dräger volumeter (Lüdeck, W Germany), which measured expired ventilation. The silica gel was weighed (Sartorius 1216 MP, Göttingen, Germany) before, often during, and always after each challenge.

Before each challenge with the ultrasonically nebulised aerosol the patient or subject breathed 40 l of room air through the circuit. FEV₁ was measured before and after this procedure to determine whether any change occurred in response to the inhalation of ambient air. A fall in FEV₁ greater than 15% of the initial value excluded the person from study at that time. At the beginning of the challenge 5 or 10 l of the nebulised aerosol was inhaled and 30 seconds later three or four measurements of FEV₁ were made. If during this initial challenge FEV₁ was found to have fallen by 10% or more a further 5–10 l of the aerosol was inhaled, and 30 seconds later a subsequent measurement of FEV₁ was made. If the reduction in FEV₁ was less than 10% the volumes of aerosol used in subsequent tests were 20 l, 40 l, 80 l, 80 l, and 80 l, until a fall in FEV₁ of at least 20% from the pre-challenge value was recorded or 310 l had been inhaled. Two minutes elapsed between the end of one challenge and the beginning of the next.

The cumulative dose of water delivered to patients was determined from their total ventilation on the basis of the regression equation for the output of the nebuliser. By subtracting the weight of

exhaled water absorbed by the silica gel we could also determine the dose of water retained by the patient.

Those patients in whom severe airways obstruction was induced by the aerosols had their recovery aided by inhaling 1 ml salbutamol (10 mg) from a Hudson nebuliser. In other patients recovery from challenge was followed by careful observation for 15 minutes.

To determine the reproducibility of the airway response 12 patients had a second challenge with distilled water performed within six months of the first. In a separate group of 11 patients the effect of a repeat challenge with distilled water after a 40-minute interval was investigated to determine whether a refractory period was present after the first challenge. Since heating occurs in nebulisers with continued use, the effect of changing the temperature from 22°C to 35°C was measured in 10 patients. The temperature of the inhaled solution was measured 10 cm from the mouth with a thermistor (No 408, Yellow Springs, USA).

The effect of sodium cromoglycate (20 mg) and (separately) of atropine methonitrate (0.1–1.0% for 10 minutes) was investigated in nine patients who were challenged with both distilled water and 3.6% saline. A separate group of nine patients were challenged with distilled water after the administration of verapamil hydrochloride (12.5 mg). All medications were delivered as aerosols (10–15 minutes before challenge) through a Hudson mask and Acorn nebuliser which was attached to a cylinder of compressed air giving a driving pressure of 10 lb/in² (69 kPa). The Acorn nebuliser delivered particles in the range of 2–10 μm . In the verapamil study isotonic saline (5 ml) was administered by the Acorn nebuliser as a placebo control 10–15 minutes before challenge with distilled water.

A dose-response curve was drawn for each patient relating the fall in FEV₁ (expressed as a percentage of the pre-challenge value) after each challenge (that is, 10 l, 20 l, 40 l, etc) to the cumulative dose of aerosol water required to induce that fall in FEV₁. The dose of aerosol water was determined from the ventilation required to induce the fall in FEV₁ by using the appropriate equation for the output of the nebuliser (see below).

Bronchial reactivity to the aerosols was assessed in several ways. Firstly, the dose (in ml) of the aerosol water required to induce a fall in FEV₁ of 20% of the pre-challenge level was determined from the dose-response curve for each patient. In this way the sensitivity to inhaled water could be compared within the patient population. Secondly, the response in FEV₁ was compared after the same dose of an aerosol (either distilled water or 3.6% saline)

had been given on separate occasions to the same patient.

An index of protection was used to assess the effect of a drug and was calculated as the difference between the fall in FEV_1 induced by challenge after pretreatment and the fall induced by challenge without pretreatment, expressed as a percentage of the fall induced by challenge without pretreatment. A value for protection greater than 60% has been taken as a significant drug effect.

Normal predicted values for FEV_1 were taken from the data of Goldman and Becklake.³

Regression coefficients were determined by the standard methods described by Snedecor and Cochran.⁴ The coefficient of variation for repeated measurements in the same subjects was determined by the standard deviation of the differences between the tests expressed as a percentage of the overall mean. A *t* test was used to determine the significance of differences between paired values in the same subject. A *p* value less than 0.05 was taken as statistically significant.

Results

The output of the ultrasonic nebuliser was constant and linearly related to the total volume taken through the silica gel for each test. The output was unaffected by temperature, flow rate, or frequency of respiration simulated by the motor blower; but the length of tubing between the nebuliser and motor blower had a small effect. The regression equations for the output and volume for both lengths of tubing used are given in table 1 (equations 1 and 2).

There was a small reduction in FEV_1 from the resting value in response to breathing 40 l of room air—mean (SD) 4.96% (7.9) in the asthmatics and 1.2% (1.8) in the normal subjects. All patients had

PD 20 FEV_1

Fig 1 Dose of ultrasonically nebulised distilled water (ml) required to induce a 20% reduction in forced expiratory volume in one second from the pre-challenge value (PD₂₀ FEV_1) in 55 patients with clinically recognised asthma (closed circles). An inhaled dose of water (33 ml) was given to 16 normal subjects (open circles) who had less than a 10% reduction in FEV_1 .

a fall in FEV_1 of 20% after the inhalation of distilled water and 3.6% saline. No normal subject had a fall in FEV_1 of 20% or more of the initial value and the challenge was terminated after 33 ml water or 3.6% saline had been given. The delivered doses of water required to induce a 20% fall in FEV_1 (PD₂₀) in the 55 patients are shown in figure 1. There was a wide variation in the dose of water required to induce the same fall in FEV_1 . Twenty-eight (51%) of the patients had a PD₂₀ of 2 ml or less and 48 (87%) had a PD₂₀ less than 10 ml. Seven patients however,

Table 1 Regression equations for (1 and 2) the output of the nebuliser (ml) in relation to the volume (litres) of aerosol delivered; (3 and 4) the resting level of forced expiratory volume in one second (FEV_1) expressed as percentage of predicted volume (R/P%) in relation to the dose (ml) of water required to induce a 20% fall in FEV_1 (PD₂₀); (5) the FEV_1 R/P% in relation to that part of the delivered dose which was retained (DR); (6) the delivered dose (DD) in relation to dose retained (both ml)

Equation No	x	y	n	a	b	r	p
1	Litres*	ml	18	0.107	-0.21	0.97	<0.001
2	Litres†	ml	18	0.095	+0.11	0.97	<0.001
3	FEV_1 R/P%	PD ₂₀	55	0.16	-8.65	0.52	<0.001
4	FEV_1 R/P%‡	PD ₂₀	48	0.035	-0.15	0.25	NS
5	FEV_1 R/P%	DR ml	44	0.03	67.2	0.09	NS
6	DD ml	DR ml	44	1.16	-4.43	0.98	<0.001

x = independent variable; y = dependent variable; n = number of observations; a = slope of line; b = intercept; r = correlation coefficient; and p = statistical probability.

*Tube length 67 cm.

†Tube length 149 cm.

‡Omitting seven patients with PD₂₀ > 10 ml.

Fig 2 Individual values for the dose of water required to induce a 20% reduction in FEV_1 ($PD_{20}FEV_1$) in relation to the pre-challenge value of FEV_1 expressed as a percentage of the predicted value.

required up to 24 ml to induce a 20% fall in FEV_1 .

The levels of FEV_1 before challenge (after the inhalation of 40 l room air) varied between patients (mean percentage predicted (SD) 83.4% (19.7)). The relationship between the delivered dose required to induce a 20% fall in FEV_1 and the pre-challenge level of FEV_1 is illustrated in figure 2. For the 55 patients there was a significant correlation between the resting level of FEV_1 and the PD_{20} . The relationship was no longer evident, however, when the seven patients with a PD_{20} greater than 10 ml were excluded (table 1, equation 4).

In 11 patients who had a mean maximum fall in FEV_1 of 42.6% (SD 7.7) the values for FEV_1 returned to 110.6% (42.0) of the pre-challenge level within 15 minutes after the administration of salbutamol. In 21 patients (mean fall in FEV_1 31.9% (SD 8.5) in whom spontaneous recovery was allowed to occur the values for FEV_1 returned to 79.0 (SD 11.7) of the pre-challenge level within 15 minutes.

The relationship between the dose delivered and the dose of water retained is given in table 1 for the 44 asthmatic patients in whom it was measured. The mean percentage of the delivered dose retained by the 44 asthmatics was 69.6% (SD 6.4) and for the 16 normal subjects 64.3% (10.4). There was no correlation between the amount of water retained and the resting level of FEV_1 expressed as a percentage of the predicted value (table 1).

Individual values for the patients who performed two challenge tests with distilled water are given in table 2. For the 12 patients who performed two tests within six months there was no significant difference in the pre-challenge levels of FEV_1 expressed as a percentage of the predicted value (test 1 83.7% (SD 19.0), test 2 81.9% (SD 21.4)). There was no significant difference in the percentage fall in FEV_1 recorded after an equivalent dose of water and the coefficient of variation for the two tests was 30%.

There was a highly significant reduction in the response in FEV_1 when the same dose of water was given after a 40-minute interval ($p < 0.001$). For this group of 10 patients the levels of FEV_1 measured before the second test (72.8% (18.7) of predicted) were significantly lower ($p < 0.005$) than the values for FEV_1 observed before the initial challenge (81.8% (16.9) of predicted). Although the reduction in FEV_1 was significantly less for the same dose of water delivered, bronchial reactivity was still evident at higher doses of water. Seven of the 10 patients still had falls in FEV_1 greater than 20% of the initial level. Thus complete refractoriness did not occur in these subjects. For the remaining three subjects (Nos 20, 21, and 23) a fall in FEV_1 greater than 20% was not recorded after the inhalation of more than 17 ml, when the test was terminated.

In eight of the 10 patients who performed an inhalational challenge with distilled water inspired at a temperature of 22.2° (SD 1.6°) C and 35.8° (0.9°) C

Table 2 Individual values for the provoking dose (PD ml) of water and the change in forced expiratory volume in one second as a percentage of the pre-challenge value (% fall in FEV₁) at this dose for repeat challenge within six months* and after 40 minutes† and with change in the temperature of the inhaled water‡

% fall in FEV ₁ * Case No PD ml Test 1 Test 2				% fall in FEV ₁ † Case No PD ml Test 1 Test 2				% fall in FEV ₁ ‡ Case No PD ml Test 1 Test 2			
1	1.9	33.5	35.5	13	1.9	37.3	17.8	24	29.6	40.2	0
2	0.9	58.0	24.0	14	7.3	26.1	11.4	25	6.8	39.8	0
3	1.4	42.0	34.9	15	3.0	42.1	17.7	26	7.3	26.9	29.1
4	3.0	28.1	42.9	16	5.1	35.2	10.5	27	10.6	28.1	30.0
5	1.4	22.0	20.7	17	0.9	31.0	15.6	28	10.6	22.9	30.0
6	1.9	36.9	30.5	18	3.0	39.9	16.3	29	1.5	20.0	28.3
7	1.4	48.9	36.9	19	1.4	29.5	12.5	30	2.5	25.0	17.5
8	6.2	29.3	31.1	20	8.3	26.9	7.5	31	14.2	12.5	30.6
9	1.9	51.0	42.0	21	15.8	32.0	4.9	32	1.5	42.7	34.9
10	20.1	30.0	21.0	22	1.9	29.8	6.0	33	2.5	46.0	20.5
11	1.9	43.0	45.8	23	12.6	46.2	27.5	—	—	—	—
12	24.3	21.0	18.6	—	—	—	—	—	—	—	—
Mean		37.8	32.0			34.2	13.4			30.4	22.1
SD		11.5	8.3			6.5	6.5			11.1	12.7
P			NS				<0.001				NS

‡Test 1: mean inspired temperature (T_i) 22°C ± 1.6; test 2 T_i 35.8 ± 0.9.

the response was reproducible. One patient (No 24) had no response after 29 ml aerosol had been inhaled at 36°C. A second patient (No 25), who had no reduction in FEV₁ at the equivalent dose (6.8 ml) of water inhaled at 36°C, had a 27% fall in FEV₁ after 22 ml, showing that bronchial reactivity was still present at the higher temperature.

Individual values for the percentage fall in FEV₁ after the same dose of water or 3.6% saline had been delivered on separate occasions with and without prior medication with sodium cromoglycate, atropine, and verapamil are given in table 3. A dose-response curve is illustrated for one patient in figure 3. None of the drugs administered induced a significant change in FEV₁ in the 15 minutes before challenge. Similarly, there was no change in FEV₁ after the inhalation of 5 ml 0.9% saline given as a placebo for verapamil.

When sodium cromoglycate was given before challenge the reduction in FEV₁ for the same dose of water or saline was less in all patients. Individual values for the percentage protection afforded by sodium cromoglycate, atropine, and verapamil are given in table 3. A value of 60% was taken as significant protection from the drug. This value is twice the value for the coefficient of variation recorded in the group of 12 patients who had two challenge tests repeated within six months.

For the equivalent dose of water, sodium cromoglycate afforded a mean protection (SD) of 81.8% (20.3) and eight of the nine patients had less than 40% of the mean response observed on the control. Similarly, with the same dose of 3.6% saline sodium cromoglycate gave significant protection to seven patients and the mean index of protection was 75.7% (SD 27.6). The response to atropine was

Table 3 Individual values for the provoking dose (PD ml) of water and saline and the change in forced expiratory volume in one second expressed as a percentage of the pre-challenge value (% fall in FEV₁) induced by that dose with and

Water challenge: % fall in FEV ₁				
Case No	PD ml	Control	SCG	Atropine
34	1.9	47.3	7.0 (85)	46.5 (2)
35	3.0	19.0	13.0 (32)	48.8 (0)
36	1.4	39.2	1.5 (96)	10.5 (73)
37	24.3	24.2	5.1 (79)	2.0 (92)
38	1.9	36.9	7.5 (80)	33.9 (8)
39	0.9	48.8	3.3 (93)	19.5 (60)
40	2.5	48.9	11.0 (78)	34.6 (29)
41	5.1	45.4	0 (100)	4.0 (91)
42	3.0	28.1	2.1 (93)	12.0 (57)
Mean		37.5	5.6 (81.8)	23.5 (45.8)
SD		11.3	4.4 (20.3)	17.9 (37.0)
P			<0.001	
P			NS

Fig 3 Change in forced expiratory volume in one second expressed as a percentage of the pre-challenge value (% fall FEV₁) in response to the inhalation of water alone on two occasions and 3.6% saline alone (solid lines) and after pretreatment with sodium cromoglycate (SCG) and atropine methonitrate in one patient (case 40).

more variable. Only four of the nine patients had 60% or greater protection after the same dose of water and three had protection after the equivalent dose of saline had been given. Only one of the nine patients challenged with water after premedication with verapamil had significant protection afforded by the drug.

Discussion

The results of this study clearly show that there is a range of bronchial reactivity in response to the inhalation of ultrasonically nebulised distilled water in the asthmatic population. In an individual, however,

the response is reproducible when the test is performed on separate days and in most patients it is independent of the temperature of the inhaled solution, at least from 22° to 36°C.

The technique described here for inhalational challenge is simple and inexpensive and it requires little co-operation from the patient since tidal breathing is used. We have observed few side effects other than cough, which was unrelated to the presence or absence of bronchoconstriction.¹ Provided that the output characteristics of the nebuliser are known, it is simple to calculate the dose of aerosol delivered from the subject's expired volume.

In 51% of the patients a positive response to

without treatment with sodium cromoglycate (SCG), atropine, and verapamil (values for percentage protection afforded by the active drugs given in brackets)

SCG challenge: % fall in FEV ₁				Water challenge: % fall in FEV ₁			
e No	PD ml	Control	SCG	Atropine	Case No	PD ml	Verapamil
12.6		37.8	2.0 (95)	20.5 (46)	43	20.1	32.8 (0)
4.1		31.0	0 (100)	13.5 (56)	44	1.9	44.5 (6)
0.9		22.7	2.8 (88)	47.6 (0)	45	7.3	10.4 (74)
11.5		27.7	19.5 (30)	4.0 (86)	46	0.3	19.5 (38)
3.0		35.7	5.0 (86)	16.2 (55)	47	3.0	32.8 (0)
0.9		40.9	0 (100)	29.8 (27)	48	24.4	13.0 (35)
2.5		49.1	11.0 (78)	13.5 (73)	49	5.1	23.7 (15)
9.4		19.8	5.0 (75)	27.6 (0)	50	7.3	20.6 (34)
5.1		24.6	17.5 (29)	8.0 (67)	51	15.8	19.8 (21)
		32.1	8.0 (75.7)	20.1 (38.9)			24.1 (24.8)
		9.5	8.3 (27.6)	13.3 (30.5)			10.8 (23.7)
		<0.001					NS
		NS					

ultrasonically nebulised water was observed within four minutes, so the test is very rapid for use as a routine provocation test. The least responsive patients, however, took 20–25 minutes to be tested.

Many patients were highly reactive to the effects of inhaled water at a time when their FEV_1 was within normal limits. It was not possible, however, to predict sensitivity to the inhaled water from the resting level of FEV_1 in the 48 patients who had a PD_{20} less than 10 ml. In 16 non-asthmatic subjects there was no PD_{20} recorded after the inhalation of 33 ml water or 3.6% saline. In the asthmatic patients the highest dose delivered to elicit a positive response was 23.8 ml. Since normal subjects had no response after 33 ml they would seem to be well separated from the asthmatic population.

Because there was relatively little variation in the proportion of water retained (despite enormous differences in the resting level of airways obstruction) we have not corrected the values for the delivered dose of water or saline. Although the amount of water retained was similar in the patients and normal subjects we do not know the site of deposition of the aerosol, which may have been different in the patients with airways obstruction before challenge.

It has been suggested that bronchial reactivity is enhanced in the presence of bronchoconstriction.⁵ We did not observe an increased reactivity to water in relation to resting lung function either in the group of 55 patients or in a patient who performed the same challenge on several occasions. In fact, we observed an appreciable reduction in airway response to the same dose of water given 40 minutes later at a time when airways obstruction was still present after the initial challenge. Some bronchial reactivity was, however, still present in seven of the 10 patients.

The increased tolerance of water inhalation may be due to availability of fewer "osmosensitive" receptor sites or to failure of the water to reach the site as a result of a change in membrane permeability. Perhaps changes in osmolarity within the respiratory tract induce a "down regulation" of receptors resulting in desensitisation and subsequent tolerance. Further studies are required to elucidate the decreased responsiveness observed with a challenge repeated within an hour.

The mechanism by which a reduction in FEV_1 occurs in patients with asthma in response to the inhalation of water and 3.6% saline is unknown. The considerable increase in FEV_1 after the administration of nebulised salbutamol implies that the reduction in FEV_1 which occurred after the inhalation of these aerosols was due to contraction of airway smooth muscle. The mechanism by which bronchoconstriction occurs presumably relates to the

osmolarity of the aerosol. Isotonic saline has little, if any, effect on FEV_1 when delivered by ultrasonic nebuliser¹ and it had no effect in a dose of 5 ml delivered by an Acorn nebuliser in this study. Distilled water and 3.6% saline appear to be equally potent in causing bronchoconstriction and similar responses in FEV_1 have been observed in our laboratory for asthmatic patients challenged with 20% dextrose.¹ A significant bronchoconstrictor stimulus is unlikely to be explained by the fact that the aerosol was inhaled at room temperature since in eight patients the response was reproducible when the temperature of the aerosol was increased to 36°C.

The observation that sodium cromoglycate was effective in inhibiting the response in all patients suggests several possibilities. Mediators from mast cells in the bronchial mucosa may be released in response to hypotonic and hypertonic solutions. Mast cells *in vitro* are known to release histamine in hypotonic solutions and basophils have been reported to release histamine in hypertonic solutions.^{6,7} Possibly sodium cromoglycate protects the cell against conformational changes in response to change in the osmotic pressure of the surrounding fluid.⁸ Transient changes in the environment of mast cells or irritant receptors may be all that is required to induce mediator release and smooth muscle contraction, either directly or via the vagus nerve. It is now thought that sodium cromoglycate may reduce reflex bronchoconstriction by an action on the post-ganglionic arm of the vagal reflex, but this has been shown only in dogs.⁹

A protective effect was noted in some patients after pretreatment with atropine, which suggests that reflex bronchoconstriction may have been occurring in these patients at least. Others, however, had an increased response after atropine, which makes the results difficult to interpret. Although a 1% solution was used, most patients complained of a severe dry mouth and throat and for this reason the dose was reduced to 0.1% for two patients (Nos 34 and 37). Patient 36 was as well protected by 0.1% on challenge with water as by 1.0% on challenge with 3.6% saline. The period of 10–15 minutes between administration and challenge was insufficient to observe the usual bronchodilating effect of atropine,¹⁰ but it is long enough for atropine to prevent induced asthma.¹¹ Allegra and Bianco² made similar observations in studying the effect of sodium cromoglycate but failed to show an inhibition of the airway response to distilled water after pretreatment with the anticholinergic ipratropium bromide.

Since mast cell release is calcium dependent it was considered that verapamil (a calcium antagonist)

might inhibit the response. If mast cells are osmotically labile, however, calcium is unlikely to be required for the release of mediators. The failure of verapamil in most patients therefore does not seem surprising. A dose of 12.5 mg was chosen as it is well tolerated and has been shown to inhibit exercise-induced asthma in some, though not all, patients.¹² In a dose of 12.5 mg it is, however, ineffective in preventing histamine-induced or methacholine-induced asthma.¹³ Possibly a higher dose may have had a significant protective effect, although we have found 120 mg verapamil, given orally one hour before challenge, to be equally ineffective in protecting against water inhalation.

The Acorn nebuliser delivers particles with a mass median diameter similar to that of particles delivered by the ultrasonic nebuliser. The drugs would therefore presumably be delivered to the same site in the lung as the ultrasonic mist, although the density of the particles may not have been the same. In the study of Allegra and Bianco² the failure of ipratropium bromide may have been due to the method of delivery.

In patients in whom two inhalational challenges were carried out we compared the reduction in FEV₁ after an equivalent dose (either water or 3.6% saline) in preference to determining the change in PD₂₀ for several reasons. Firstly, many of our patients were exquisitely sensitive to small doses of water. Extrapolating a PD₂₀ from a dose-response curve when a change of 65% in FEV₁ occurred in response to the inhalation of 0.5 ml water presented some difficulties. Secondly, by using the same dose of water or saline to evaluate the effect of a repeated challenge, with or without premedication, we have been able to document changes well above the threshold of abnormal reactivity (that is, a greater than 20% reduction in FEV₁). This approach to evaluating drug treatment is commonly used in exercise-induced bronchoconstriction asthma.¹¹

Documenting the stimulus required to induce a 20% reduction in FEV₁ is a useful technique for studying sensitivity within a population of asthmatic patients. We believe that documentation of individual reactivity and the change induced by drugs may be of major clinical significance.

The results of this and an earlier study¹ from this laboratory indicate that patients with asthma are exquisitely sensitive to a change in osmolarity within the respiratory tract. We have previously suggested that the evaporation of water, which occurs from the bronchial mucosa during exercise, acts as a transient hypertonic stimulus and that this change in osmolarity may be an important mechanism in exercise-induced asthma.¹⁴

Inhalational challenges with ultrasonically nebulised hypotonic and hypertonic solutions in patients with asthma provides a useful technique for comparing the response to osmotic stimulus, whether extrinsic (for example, inhalation of fog) or intrinsic (for example, water loss by evaporation). In this way many triggering factors known to induce asthma may be shown to act through a common pathway.

RES was supported by the Maureen Thompson asthma research grant of the National Health and Medical Research Council of Australia.

References

- ¹ Schoeffel RE, Anderson SD, Altounyan REC. Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline. *Br Med J* 1981;**283**:1285-7.
- ² Allegra L, Bianco S. Non-specific broncho-reactivity obtained with an ultrasonic aerosol of distilled water. *Eur J Respir Dis* 1980;**61** suppl 106:41-9.
- ³ Goldman HI, Becklake MR. Respiratory function tests: normal values at medium altitudes and the prediction of normal results. *Am Rev Respir Dis* 1959;**79**:457-67.
- ⁴ Snedecor GW, Cochran WG. *Statistical methods*. Ames, Iowa: Iowa State University Press, 1967.
- ⁵ Tattersfield AE. Measurement of bronchial reactivity: a question of interpretation. *Thorax* 1981;**36**:561-5.
- ⁶ Findlay SR, Lichtenstein LM. Basophil "releasability" in patients with asthma. *Am Rev Respir Dis* 1980;**122**:53-9.
- ⁷ Kaliner M, Austen KF. Cyclic AMP, ATP and reversed anaphylactic histamine release from rat mast cells. *J Immunol* 1974;**112**:664-74.
- ⁸ Padawer J. Mast-cell structure: implications for normal physiology and degranulation. In: Pepys J, Edwards AM, eds. *The mast cell: its role in health and disease*. Tunbridge Wells: Pitman Medical, 1979:1-8.
- ⁹ Dixon M, Jackson DM, Richards IM. The action of sodium cromoglycate on "C" fibre endings in the dog lung. *Br J Pharmacol* 1980;**70**:11-3.
- ¹⁰ Altounyan REC. Variation of drug action on airway obstruction in man. *Thorax* 1964;**19**:406-15.
- ¹¹ Anderson SD, Seale JP, Ferris L, Schoeffel RE, Lindsay DA. An evaluation of pharmacotherapy for exercise-induced asthma. *J Allergy Clin Immunol* 1979;**64**:612-24.
- ¹² Patel KR. Calcium antagonists in exercise-induced asthma. *Br Med J* 1981;**282**:932-3.
- ¹³ Patel KR. The effect of verapamil on histamine and methacholine-induced bronchoconstriction. *Clin Allergy* 1981;**11**:441-7.
- ¹⁴ Anderson SD, Schoeffel RE, Follet R, Perry CP, Davis-kas E, Kendall M. Sensitivity to heat and water loss at rest and during exercise in asthmatic patients. *Eur J Respir Dis* 1982;**63**:459-71.